Comparison of PD and NPD using landmark analysis at 3 months

CharacteristicsPD Group N (%)n = 49NPD Group N (%)n = 39p-value
Mean age, years (SD)66 (10.20)64 (9.61)0.401
Male Gender33 (67)33 (85)0.107
ECOG PS0.106
 023 (52)10 (27)
 115 (34)18 (49)
  > 26 (14)9 (24)
IMDC Risk Group0.139
 Favorable8 (17)4 (10)
 Intermediate35 (73)24 (63)
 Poor5 (10)10 (26)
Prior Nephrectomy35 (97)30 (97)1.000
No of prior systemic therapies, median, No. (range)
No of prior systemic therapies0.404
 125 (51)15 (38)
 210 (20)14 (36)
 310 (20)6 (15)
  > 43 (6)4 (10)
Common prior systemic therapies
 Sunitinib38 (78)24(61)0.161
 Pazopanib15 (31)15 (38)0.586
 Axitinib18 (37)17 (44)0.665
Sites of metastases at baseline
 Brain7 (18)7 (14)0.862
 Bones13 (33)24 (49)0.208
 Lungs33 (85)31 (63)0.046
 Liver14 (36)12 (24)0.352
 Lymph Nodes31 (79)26 (53)0.019
 Pleural13 (33)5 (10)0.016
 Adrenal9 (23)11 (22)1.000

Two patients were excluded from this analysis because of lack data regarding their PD status